A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2022-03-16
AEs
3
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-04-11 (study day 12); relationship: N
severe
serious
assessed
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-04-11 (study day 12); relationship: not assessed; serious criteria: hospitalization
moderate
assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-04-25 (study day 26); relationship: not assessed
Data queries
No data queries.